SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.
Keshtgarpour
Mani
M
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA.
Dudek
Arkadiusz Z
AZ
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D000077210:Sunitinib; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib